Drugs / RPCAR01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06968195 | Jul 2026 → May 2028 | hepatocellular carcinoma | Roswell Park Cancer Institute | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPCAR01 | “RPCAR01 is a genetically modified T cell (a part of the immune system) product that targets GPC3 and decreases the inhibition of T cells by a protein called transforming growth...” NCT06968195 ↗ |
| Action | Deplete | “identify and kill GPC3 tumor cells” NCT06968195 ↗ |
| Modality | Cell therapy | “RPCAR01 is a genetically modified T cell (a part of the immune system) product” NCT06968195 ↗ |
| Route | Intravenous | “RPCAR01 CAR T cells IV over 15 minutes on day 1” NCT06968195 ↗ |
| Target | GPC3 | “product that targets GPC3” NCT06968195 ↗ |